Study on the Efficacy and Safety of Avatricopal in Patients With CLD Complicated With Thrombocyto… (NCT06642740) | Clinical Trial Compass
By InvitationNot Applicable
Study on the Efficacy and Safety of Avatricopal in Patients With CLD Complicated With Thrombocytopenia
China69 participantsStarted 2024-06-01
Plain-language summary
In this study, patients with chronic liver disease undergoing selective invasive and minimally invasive surgery combined with thrombocytopenia were enrolled. After enrollment, liver disease treatment was supplemented with avatripopal for 5 days. Biochemical indexes of avatripopal were monitored during treatment and after withdrawal. The proportion of patients with platelet count ≥50×10\^9/L on the day of selective invasive and minimally invasive surgery was analyzed. The incidence of adverse events was observed.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Voluntarily join the study and sign the informed consent;
* Age ≥18 years old, male or female;
* Baseline platelet count \< 50×10\^9/L;
* Patients with chronic liver disease undergoing elective invasive and minimally invasive surgery;
* No fertility requirements.
Exclusion Criteria:
* History of arterial or venous thrombosis within 6 months prior to baseline;
* Plan to receive platelet transfusion or platelet-containing blood products within 7 days prior to baseline visit;
* Anticoagulant or antiplatelet therapy cannot be suspended before surgery according to the standard (low-dose aspirin is allowed to continue);
* currently receiving treatment with recombinant human thrombopoietin or thrombopoietin receptor agonists (such as rhTPO, Etopopal, or romipristine);
* The subjects had severe arteriosclerosis, cerebral thrombosis tendency, coronary artery stenosis \> 70%;
* Patients with a history of arterial or venous thrombosis within 6 months before enrollment;
* Patients with known portal vein blood flow velocity \< 10 cm/s or previous portal vein thrombosis within 6 months before enrollment;
* Prior to enrollment, any known primary blood history (e.g., immune thrombocytopenia, myelodysplastic syndrome, aplastic anemia);
* A known history of hereditary prethrombotic syndrome prior to admission (e.g., VLeiden mutation, prothrombin G20210A mutation, or hereditary antithrombin III (ATIII) deficiency);
* A history of major cardiovascular disease within the …
What they're measuring
1
Proportion of patients with platelet count ≥50×10^9/L on the day of elective invasive and minimally invasive surgery.